Helius Medical Technologies logo
Helius Medical Technologies HSDT
$ 1.65 -2.37%
report update icon

Quarterly report 2026-Q1
added 05-15-2026

Helius Medical Technologies Income Statement 2025-2011 | HSDT

Brief overview of revenue and earnings at Helius Medical Technologies

The conclusions below are based on five years of reported results. Revenue at Helius Medical Technologies moved from 661 thousand dollars in 2020 to 6 million dollars in 2025. Overall revenue changed by +810.3%, equal to an annualized rate of about 55.5%. This pace points to rapid expansion of the business.

The gross result shifted from 273 thousand dollars to 5.5 million dollars, or +1920.9%. Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. At the margin level, the figure shifted from 41.3% to 91.7%. A wider margin shows that the economics of the core business improved.

EBITDA changed from −14 million dollars to −244 million dollars (−1638.9%). The operating result developed less favorably than sales. The EBITDA share of revenue changed from −2121.5% to −4052.5%. Operating return per unit of revenue declined.

Comparing the endpoints shows a move from −14.1 million dollars to −40.9 million dollars. Larger losses indicate rising pressure on the business.

Overall conclusion

Signs of deterioration dominate the five-year picture. The financial profile benefits from sales growth and improving gross profitability. The most visible risks are a weaker final result, pressure on operating profitability and a low EBITDA margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Helius Medical Technologies

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

4.03 B 3.76 M 3.54 M 72.9 K 11.4 M 16.1 M 25.8 M 170 M 196 M 74.5 M 125 M - - - -

Shares

22 M 3.58 K 608 K 270 K 2.46 M 1.2 M 753 K 651 K 532 K 380 K 326 K - - - -

Historical Prices

183 1.05 K 5.83 0.27 4.64 13.6 31.9 248 422 285 133 457 - - -

Net Income

-40.9 M -11.7 M -8.9 M -14.1 M -18.1 M -14.1 M -9.78 M -28.6 M -28 M -6.88 M -8.89 M -1.07 M - - -

Revenue

6.02 M 520 K 644 K 787 K 522 K 661 K 1.5 M 478 K - - - - - - -

Cost of Revenue

500 K 582 K 583 K 463 K 298 K 388 K 846 K - - - - - - - -

Gross Profit

5.52 M -62 K 61 K 324 K 224 K 273 K 650 K - - - - - - - -

Operating Income

-244 M -13.9 M -12.4 M -15.5 M -18.1 M -14.4 M -24 M -26.7 M -22.9 M -9.32 M -9.81 M -1.07 M -8.52 M - -

Interest Expense

- - - - - - - - - 46.9 K 176 K - - - -

EBITDA

-244 M -13.9 M -12.4 M -15.4 M -18 M -14 M -23.9 M -26.6 M -22.8 M -9.17 M -8.84 M -1.07 M -8.52 M - -

Operating Expenses

249 M 13.8 M 12.5 M 15.8 M 18.4 M 14.7 M 24.6 M 27.2 M 22.9 M 9.32 M 8.86 M - - - -

General and Administrative Expenses

23.1 M 10.2 M 9.27 M 10.6 M 12.2 M - - 17.2 M 8.47 M 5.67 M 4.26 M 896 K 4.27 M - -

All numbers in USD currency

Quarterly Income Statement Helius Medical Technologies

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

76.7 M 10.7 M 123 K 7.56 M 4.94 K 4.95 K 3.32 K 817 K 715 K 668 K 564 K 564 K 564 K 356 K 3.93 M 3.79 M 3.78 M 2.33 M 2.32 M 2.04 M 1.48 M 1.29 M 1.16 M 885 K 878 K 25.9 M 25.9 M 25.8 M 25.8 M 23.4 M 22.9 M 20.3 M 20.2 M 19.2 M 18.3 M 17.6 M 16.9 M 84.4 M 81 M 71.8 M 65 M 64.4 M 64.1 M 63.1 M 63.1 M 63.1 M 51 M 38.8 M - - - - - - - - - - - -

Net Income

-99.8 M -353 M -9.83 M -3.84 M - -3.69 M -1.61 M -2.52 M - -3.66 M -1.65 M -2.49 M - -1.03 M -3.81 M -4.35 M - -4.69 M -5.98 M -3.36 M - -3.48 M -3.36 M -4.76 M - -5.59 M -186 K 1.32 M - -4.52 M -17.8 M -1.16 M - -12.9 M -5.68 M -5.68 M - -2.99 M -3.08 M -3.83 M -2.43 M 1.79 M -769 K - -2.48 M -2.48 M -3.76 M -1.56 M - - - -8.52 M - - - - - - - -

Revenue

3.62 M 697 K 43 K 49 K - 51 K 182 K 135 K - 143 K 256 K 111 K - 196 K 119 K 190 K - 109 K 71 K 84 K - 131 K 133 K 207 K - 150 K 518 K 677 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

180 K 103 K 96 K 121 K - 187 K 118 K 123 K - 187 K 184 K 122 K - 101 K 88 K 124 K - 86 K 67 K 15 K - 22 K 64 K 101 K - 89 K 212 K 236 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

3.44 M 594 K -53 K -72 K - -136 K 64 K 12 K - -44 K 72 K -11 K - 95 K 31 K 66 K - 23 K 4 K 69 K - 109 K 69 K 106 K - 61 K 306 K 441 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-99.6 M -35.4 M -3.32 M -4.01 M - -4.07 M -3.27 M -3.42 M - -3.15 M -3.22 M -3.81 M - -4.85 M -3.43 M -4.56 M - -4.37 M -6.17 M -3.5 M - -3.66 M -3.72 M -4 M - -5.74 M -5.81 M -6.82 M - -4.89 M -11.8 M -4.72 M - -5.97 M -5.98 M -5.03 M - -3.39 M -2.1 M -2.92 M -2.84 M -726 K -3.71 M - -3.09 M -3.09 M -2.76 M -1.38 M - - - - - - - - - - - -

Interest Expense

-181 K -154 K -420 K - - 233 K 71 K - - - - - - - - - - - - - - - 56 K 6 K - 11 K 13 K 11 K - - - - - - - - - -20 K - -20.4 K 26.1 K - 53 - - - - 176 K - - - - - - - - - - - -

EBITDA

-99.6 M - - -4 M - -4.06 M -3.26 M -3.41 M - -3.12 M -3.18 M -3.8 M - -4.81 M -3.38 M -4.54 M - -4.29 M -6.11 M -3.47 M - -3.63 M -3.69 M -3.96 M - -5.69 M -5.79 M -6.8 M - -4.85 M -11.8 M -4.71 M - -5.96 M -5.98 M -5.03 M - -3.39 M -2.1 M -2.92 M -2.84 M -726 K -3.71 M - -3.09 M -3.09 M -2.76 M -1.38 M - - - - - - - - - - - -

Operating Expenses

103 M 36 M 3.27 M 3.94 M - 3.93 M 3.33 M 3.43 M - 3.11 M 3.29 M 3.8 M - 4.95 M 3.46 M 4.63 M - 4.4 M 6.17 M 3.57 M - 3.77 M 3.79 M 4.11 M - 5.8 M 6.12 M 7.26 M - 4.89 M 11.8 M 4.72 M - 5.97 M 5.98 M 5.03 M - 3.39 M 2.1 M 2.92 M - 726 K 3.71 M - - - - - - - - - - - - - - - - -

General and Administrative Expenses

5.19 M 4.65 M 2.45 M 2.99 M - 2.86 M 2.46 M 2.63 M - 2.2 M 2.57 M 2.87 M - 3.39 M 2.46 M 2.82 M - 2.86 M 4.74 M 2.2 M - 2.37 M 2.39 M 2.86 M - 4.29 M 3.84 M 4.58 M - 2.58 M 8.89 M 2.16 M - 2.17 M 1.68 M 2.01 M - 1.98 M 1.45 M 1.93 M 30.4 K 724 K 2.19 M - 45.5 K 45.5 K 83.7 K 21.4 K - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Helius Medical Technologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Myomo Myomo
MYO
$ 0.93 -3.11 % $ 38.9 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Profound Medical Corp. Profound Medical Corp.
PROF
$ 7.24 -0.14 % $ 219 M canadaCanada
AxoGen AxoGen
AXGN
$ 41.37 0.53 % $ 1.91 B usaUSA
Quanterix Corporation Quanterix Corporation
QTRX
$ 3.38 -3.15 % $ 144 M usaUSA
AVITA Medical AVITA Medical
RCEL
$ 4.44 -3.69 % $ 124 M australiaAustralia
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 61.74 -1.86 % $ 9.37 B usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 32.66 0.31 % $ 28.3 B britainBritain
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 27.4 -1.23 % $ 627 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Tandem Diabetes Care Tandem Diabetes Care
TNDM
$ 18.59 4.67 % $ 1.26 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 14.14 -2.68 % $ 400 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.86 -1.95 % $ 14.6 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 11.65 -2.27 % $ 453 M usaUSA
Varex Imaging Corporation Varex Imaging Corporation
VREX
$ 10.95 -1.62 % $ 453 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.35 -4.32 % $ 21.8 M usaUSA
LENSAR LENSAR
LNSR
$ 5.25 -1.87 % $ 62.8 M usaUSA
Beyond Air Beyond Air
XAIR
$ 5.51 0.92 % $ 45.7 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Xtant Medical Holdings Xtant Medical Holdings
XTNT
$ 0.43 0.14 % $ 60 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 97.15 1.46 % $ 19.2 B usaUSA